INTRODUCTION
The need for effective glycemic control in type 1 (T1DM) and type 2 diabetes mellitus (T2DM) to prevent the development of complications is well understood. However, hypoglycemia and the fear of hypoglycemia, as well as weight gain, impair both patients' and physicians'
willingness to titrate insulin to the doses required to achieve guideline-recommended target levels of glycemia [1] [2] [3] . With the two basal insulin analogs, insulin glargine (glargine) and insulin detemir (detemir), the risk of hypoglycemia is lower than with older human insulin formulations [4] . Nevertheless, there is still room for improvement in the pharmacokinetics and pharmacodynamics of basal insulin preparations, and consequently the search has continued for a basal analog with less variability in pharmacodynamic effect and a longer duration of action than those currently available to fulfil requirements in all patients with once-daily administration.
Insulin degludec (degludec) is a nextgeneration basal insulin with an ultra-long and stable action profile and lower pharmacodynamic variability than glargine [5, 6] . Degludec has been designed to form long, soluble multi-hexamer chains upon injection into the subcutaneous tissue; insulin monomers gradually dissociate from these [7] . This mechanism of protraction results in a flat and stable pharmacokinetic and pharmacodynamic profile [6] . Degludec has a half-life of approximately 25 h in patients with T2DM [6] and a glucose-lowering effect at steady state in patients with T1DM beyond 42 h [8] .
The efficacy of degludec once daily was examined in a large clinical development program, BEGIN, which included nine 26-or 52-week trials. Three trials were versus glargine in basal-bolus therapy in T1DM [9, 10] and T2DM [11] , and four trials were versus glargine in basal-oral therapy in T2DM [12] [13] [14] [15] . In addition, degludec was compared with sitagliptin in a basal-oral trial in T2DM [16] , and with detemir in a basal-bolus trial in T1DM.
In all seven trials in which it was compared with glargine, degludec showed non-inferiority with respect to mean decrease in glycosylated hemoglobin (HbA 1c ). Rates of confirmed hypoglycemia and, in particular, nocturnal confirmed hypoglycemia, were either similar with the two insulins or significantly lower with degludec. A pre-planned meta-analysis of hypoglycemia associated with the two treatments has already been published [17] .
This meta-analysis confirmed that degludec is associated with a lower risk of hypoglycemia, in particular nocturnal confirmed hypoglycemia, compared with glargine. The reductions in hypoglycemia were even more marked in the maintenance period (i.e., after 16 weeks, when the initial up-titration was completed).
Nocturnal hypoglycemia is a particularly useful outcome for reflecting differences between basal insulins, as it is less likely than daytime hypoglycemia to be confounded by the effect of bolus insulin, meals, and activity.
Previously, confirmed hypoglycemia included both severe and non-severe events. To avoid double counting of events in health economic models, the new meta-analyses reported here regrouped the confirmed events into three mutually exclusive groups: non-severe nocturnal, non-severe daytime, and severe hypoglycemia. The division of non-severe events into daytime and nocturnal was included to provide evidence on whether the documented reduction in nocturnal events with degludec was offset by a change in daytime events.
Individual studies also demonstrate a significantly or numerically lower insulin dose with degludec compared with glargine in T1DM [9, 10] and in T2DM [12] [13] [14] [15] . In the new metaanalyses reported here, we investigated whether these findings could be confirmed.
Hypoglycemia was to obtain a comprehensive overview of all relevant differences between degludec and glargine, adding to evidence on hypoglycemia [17] and HRQoL [18, 19] .
METHODS
Trials Included in the Meta-Analysis 
Methodology of the Individual Phase 3a Trials
All of the trials included in the current meta- The treat-to-target design was used, targeted at self-measured blood glucose \5 mmol/L, based on a mean of three consecutive days' measurements. Treating to a common target, recommended by the FDA [20] , allows for interpretation of any between-treatment differences in the frequency and severity of hypoglycemia without being confounded by differences in glycemic control. The primary All the meta-analysis regression models were adjusted for trial, type of diabetes, antidiabetic therapy at screening, sex, region, and age.
Except for hypoglycemia, all the models included baseline value as a covariate.
RESULTS

Glycemic Control
As expected in treat-to-target trials, there was no statistical difference between treatments in reducing HbA 1c : degludec was non-inferior to glargine in T1DM B/B , T2DM insulin-naïve , and (Table 2) .
Insulin Dose
In T1DM B/B , the total daily dose of insulin was significantly lower, by 12%, with degludec compared with glargine (P\0.0001) ( Table 3) .
Statistical analyses were performed for both basal and bolus insulin doses to clarify the relative contribution of each to the observed reduction in total dose. These showed that the daily basal and bolus doses were both lower with degludec, with relative rates (degludec versus glargine) as follows: daily basal dose, 0.87; daily bolus dose, 0.88 (both P\0.05).
The total daily insulin dose was also significantly lower (by 10%, P = 0.0004) with degludec in T2DM insulin-naïve . In T2DM B/B , total daily insulin dose did not differ statistically between treatments (Table 3) .
Hypoglycemia Analyzed in Mutually Exclusive Groups
The actual event rates for the mutually exclusive groups used in the current metaanalysis are shown in Table 4 . Event rates for the individual trials are available in the earlier papers [11, 17] . The estimated hypoglycemia rate ratios for the current meta-analysis are shown in Table 5 . These results showed significantly lower rates of nocturnal nonsevere hypoglycemia with degludec in T1DM B/ B , T2DM insulin-naïve , and T2DM B/B (by 17, 36, and 25%, respectively; all P\0.05). With degludec, rates of daytime non-severe hypoglycemia were significantly lower than with glargine (by 17%; P\0.05) in T2DM B/B , with no statistical differences in T1DM B/B and T2DM insulin-naïve . Rate ratios for severe events, analyzed in the previous meta-analysis (and not re-analyzed, as the definition remained unchanged) [17] , were 1.12 [not significant (ns)] (T1DM B/B ); 0.14 CI confidence interval, IDeg insulin degludec, IGlar insulin glargine, n number of patients, T1DM B/B basal-bolus-treated type 1 diabetes mellitus, T2DM B/B basal-bolus-treated type 2 diabetes mellitus, T2DM insulin-naïve insulin-naïve type 2 diabetes mellitus * Significant based on 95% CI a 'Nocturnal' in the previously published analysis included all nocturnal events, severe and non-severe. In the current metaanalysis, three mutually exclusive groups were defined: non-severe nocturnal, non-severe daytime and severe hypoglycemia. The definition of, and results for, severe episodes were similar in both analyses; therefore, severe episodes are not included in the current meta-analysis b Same assumptions as above. The maintenance period is from week 16 and onwards periods are shown in Table 5 .
DISCUSSION
This meta-analysis showed that across subgroups of patients with diabetes, those treated with degludec achieve similar or significantly better results than those treated with glargine in terms of FPG and rates of hypoglycemia, with similar reductions in HbA 1c . These results are achieved with lower mean total insulin doses. Non-inferiority of degludec with respect to HbA 1c lowering was confirmed (Table 2) . Noninferiority is expected for treat-to-target trials and was indeed seen in each trial. Nevertheless, it is useful to confirm that, across different subgroups, based on patient-level data, the lower rates of hypoglycemia seen with degludec are not obtained at a cost of inferior glycemic control.
The individual trials had shown numerically [9, 11, 14] or significantly greater reductions in FPG [12, 15] with degludec. The current metaanalysis showed significantly greater reductions in FPG at trial end with degludec in both T1DM B/B and T2DM insulin-naïve (0.61 and 0.34 mmol/L, respectively) ( Table 2 ).
In the current meta-analysis of hypoglycemia analyzed in mutually exclusive groups (Table 4) , rates of confirmed hypoglycemia in T2DM were low and were generally in line with rates observed in other trials. For example, among insulin-naïve patients, the non-severe confirmed hypoglycemia rates with glargine were 2.05 and 3.0 events per patient-year, respectively, in the current meta-analysis (Table 4 ) and in the treatto-target trial (which used a similar definition, with confirmed events of B3.1 mmol/L) [21] .
Corresponding nocturnal events were 0.51 and 1.3 per patient-year, respectively.
It is striking that despite the low hypoglycemic event rates observed in trials, in the current meta-analysis, rates of nocturnal non-severe hypoglycemia were significantly lower with degludec than with glargine in all subgroups ( Table 5 ). Rates of daytime nonsevere hypoglycemia were numerically lower in T2DM insulin-naïve and significantly lower in T2DM B/B with degludec (Table 5) . Thus, the lower rates of nocturnal non-severe events observed with degludec do not occur at a cost of higher daytime rates in T2DM. In T1DM B/B , daytime non-severe rates were numerically but not statistically higher with degludec (Table 5) . These results may have been confounded by the unequal dose adjustment in the T1DM B/B trials for patients randomized from twice-daily (BID) insulin. For patients previously on BID insulin who were randomized to glargine, a 20-30% reduction in starting dose was recommended, whereas patients randomized to degludec maintained the same dose. This possibility is further supported by the fact that during the predefined maintenance phase ([16 weeks), there was no increase in the risk of daytime non-severe hypoglycemia with degludec.
Furthermore, these lower rates of nocturnal non-severe hypoglycemia with degludec were observed together with significantly or numerically greater reductions in FPG values.
Lower FPG values would normally be expected to be accompanied by higher rates of nocturnal hypoglycemia, but with degludec, the reverse was observed. This can most likely be attributed to the stable and consistent profile of degludec, with its long duration of action and lower dayto-day pharmacodynamic variability compared with glargine [5, 6] .
Hypoglycemia and fear of hypoglycemia remain barriers to achieving target levels of control [3] . In addition, hypoglycemia has negative health-economic consequences such as additional contacts with healthcare professionals and absence from work following an event, and these are particularly marked for nocturnal hypoglycemia [22] . The possibility of achieving lower FPG together with lower risk of nocturnal hypoglycemia with degludec is, therefore, valuable both to patients and in terms of overall costs.
The value to patients of the lower risk of hypoglycemia can be expressed in terms of numbers needed to treat, as reported previously [17] . In T2DM insulin-naïve , for every 100 people End-of-trial total daily insulin doses were significantly lower with degludec versus glargine in T1DM B/B and T2DM insulin-naïve (Table 3 ). This observation of lower doses with degludec confirms the findings from individual trials, with significantly lower end-of-trial mean total insulin doses as follows: in T1DM B/B , 11% lower in both the BEGIN BB T1 Long trial (P\0.001) [9] and in the BEGIN Flex T1 trial (statistical significance not reported) [10] ; and in T2DM insulin-naïve , 20% lower in BEGIN Once Asia (P = 0.0004) [14] and 11% lower in BEGIN Low Volume (P\0.05) [12] . In the third T2DM insulin-naïve trial, BEGIN Once Long [15] , mean end-of-trial doses were not statistically different for degludec and glargine.
With the exception of BEGIN Flex T1, HRQoL was measured in all of the trials included in this meta-analysis using the SF-36 questionnaire [23] , which patients completed themselves. As HRQoL results have already been published, HRQoL was not included in the current meta-analysis. For T1DM B/B , there were no significant between-treatment differences in change from baseline in HRQoL in the BEGIN BB T1 Long trial [9] . For T2DM insulin-naïve , a meta-analysis examining HRQoL changeswhich included BEGIN Once Long, BEGIN Once Asia and BEGIN Low Volume-reported that, at endpoint, the overall physical health component score was significantly better with degludec versus glargine, due primarily to a better score for degludec in the bodily pain domain [19] . In the mental domains, the vitality score was significantly better with degludec. For T2DM B/B , HRQoL scores were significantly better with degludec for the domain of bodily pain [11] . A further metaanalysis evaluated HRQoL expressed in terms of health utility score (a value for estimating quality of life) across all six BEGIN trials in which HRQoL was measured [18] . Degludec was associated with a modest but statistically significant improvement in health utility compared with glargine. 
CONCLUSIONS
